What We Do:
NIDA’s HIV/AIDS research grants are assigned to the Divisions within NIDA based on referral guidelines. Within each Division, there are staff with HIV/AIDS programmatic interests. Brief descriptions of their program areas and e-mail addresses are listed below. Please feel free to contact the appropriate program staff to discuss potential applications.
Division of Therapeutics and Medical Consequences of Drug Abuse
- Jag Khalsa – medical/clinical consequences of drug abuse and co-occurring infections including HIV, hepatitis (HCV), STDs, TB, and others; interactions between drugs of abuse and medications used in the treatment of drug addiction
- Will Aklin – Neurobehavioral processes underlying HIV risk (impulsivity and risky decision-making) as treatment targets, behavioral and integrative treatments for HIV, integration of risk reduction strategies into drug abuse treatment, treatments that promote adherence to HIV medications
Division of Neuroscience and Behavior
- Roger Sorensen – investigations of the neuropathology and neurological disorders caused by drug abuse and HIV/AIDS, including interactions of drugs of abuse, host and viral factors on neuronal and glial function, neuroplasticity, and the neuropathogenesis of neuronal, cognitive, and motor deficits due to drug abuse and HIV infection
- Yu Lin – cognitive, neuropsychological and neurobiological sequelae of HIV/AIDS; neuroinflammation; and co-morbidity
- Vishnu Purohit – systems biology approach for research on HIV-Associated Neurological Disorders [HAND] with drug abuse and antiretroviral therapy (ART), the impact of drugs of abuse in the development of HIV latency/ reservoirs in the brain, and the development of new technologies to increase the penetration of the brain-vascular system by ART.
- John Satterlee – molecular aspects of HIV/AIDS progression and latency and their interaction with substance abuse -
Division of Epidemiology, Services, and Prevention Research
- Elizabeth Lambert – behavioral and social epidemiology and natural history research on HIV/AIDS and other infectious diseases among drug users, their social networks, and their communities; behavioral and molecular epidemiology of host and viral factors that increase risks for the acquisition and transmission of HIV and co-infections, including drug-resistant viruses
- Peter Hartsock – mathematical modeling of HIV and other infectious diseases, molecular epidemiology, and international studies.
- Richard Jenkins – behavioral and social aspects of preventive biomedical trials;; community, structural, and policy-level prevention interventions; international HIV prevention; innovative research methods and multi-method research designs; preventive intervention with men who have sex with men; prevention interventions with co-morbid populations
- Dionne Jones – treatment services for HIV/AIDS patients, including women and minorities and those at risk of infection; HIV/AIDS interventions and health and behavioral outcomes
- Shoshana Kahana – behavioral interventions for comorbid conditions, specifically traumatic stress and drug use, in adolescent and adult populations; integrating HIV risk reduction into drug abuse treatment; and the development and effective implementation of interventions that promote treatment adherence in populations with chronic health conditions, including HIV.